针对由卡波西斯肉瘤引起的恶性瘤中缺氧诱导因素的向与疹病毒相关
David A Davis1, Prabha Shrestha1, Robert Yarchoan1
1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.
Global health & medicine
|November 1, 2024
概括
低氧诱导因子 (HIF) 在卡波西肉瘤相关疹病毒 (KSHV) 相关的癌症中起着关键作用. 针对HIFs的抑制剂显示为这些KSHV恶性瘤的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 分子生物学分子生物学
背景情况:
- 卡波西的肉瘤相关性疹病毒 (KSHV),也被称为人类疹病毒-8,与几种恶性瘤有关.
- 低氧诱导因子 (HIF) 对于KSHV的维持,受感染细胞的生长和病毒通过性反应激活传播至关重要.
- 在过去的二十年里,广泛的研究已经阐明了HIF在KSHV病变发生过程中的重要作用.
研究的目的:
- 突出低氧诱导因子 (HIF) 抑制剂在与KSHV相关的恶性瘤中的潜在治疗应用.
- 审查有关HIF和KSHV疾病的当前研究环境.
- 评估支持针对KSHV相关疾病的HIF向药物的临床前和临床证据.
主要方法:
- 审查现有的科学文献和研究结果.
- 在KSHV模型中对HIF抑制剂的临床前数据的分析.
- 对各种癌症中HIF抑制剂的临床试验数据的检查.
主要成果:
- HIF是KSHV相关癌症生命周期和进展的组成部分.
- 目前,许多HIF抑制剂正在进行癌症治疗的临床评估.
- 临床前和临床证据表明,针对HIF是KSHV恶性瘤的可行策略.
结论:
- 低氧诱导因子的抑制剂代表了卡波西肉瘤相关疹病毒 (KSHV) 相关疾病的有前途的新疗法.
- 需要进一步的研究和临床试验,以确定HIF抑制剂在治疗KSHV恶性瘤中的有效性和安全性.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.0K